Details For Selected Brain Tumor Treatment

Sponsored By

Please Click On The Above Banner For More Details

Back to New Treatments List


		Treatment Name:		A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma

		Phase:		Phase 1/2

		Treatment ID#:		1766

		Age Group:		Adults Only

		Min Karnofsky Score:		60: Requires occasional assistance but is able to care for most of own needs

		Conditions:		Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed

		Last Updated:		04/21/2009

		Tumor Types:		Glioblastoma Multiforme


		Comments:		RATIONALE: Tandutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

		Treatment Type:		Less-Toxics Immunological, Biological or Targeted Therapy

		Contact:		Tracy Batchelor MD, MPH Executive Director Mass. General Hospital - Brain Tumor Center Brain Tumor Center Suite 315, Cox Building Boston, MA 02114 USA Phone: 617-724-8770 Fax: (617)724-8769 E-mail: jkracher@partners.org Website: brain.mgh.harvard.edu

Last updated refers to the date when our listing for each treatment was last updated.
ID is a combination of our internal ID and the official ID for the trial, if any.
Min Karnofsky is a general guide to how well you have to function to use this treatment

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By